Key Drivers
- Net cash
- Cash burn
- Share dilution
AIAI Summary
TSHA has shifted from a broad gene-therapy speculation to a high-upside but highly binary single-asset bet on TSHA-102 for Rett syndrome, where the key investment question is now whether encouraging data and FDA support can translate into an approvable BLA before dilution and execution risk erode per-share upside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Net cash
- •Cash burn
- •Share dilution
TSHA has a strong net cash position and ample liquidity, but persistent losses, negative free cash flow, and dilution make it a heavily cash-burning business.
Price Behavior
Key Price Behavior Insights:
- •Uptrend intact
- •Resistance stall
- •Choppy pullback
TSHA has trended higher over the last month and is still holding above its June breakout, but fading momentum and repeated stalls near $6.80-$6.95 leave the rally constructive yet fragile until it clears resistance.
Recent drop from $6.94 to $6.53 shows a choppy pullback and rising retracement risk
Sentiment & News
Key News Insights:
- •Clinical momentum
- •Large financing
- •BLA potential
Taysha is advancing TSHA-102 in Rett syndrome with strong clinical updates and a ~$200 million equity raise to support a potential accelerated BLA filing in 1H27.
The combination of encouraging efficacy data and a strengthened balance sheet improves TSHA's near-term execution outlook and supports investor confidence
Similar Companies in Healthcare
Other companies in the same sector with AI ratings